54 recruiting, 37 unknown, 36 not yet recruiting, 21 completed. 87 Phase 2, 24 Not applicable, 12 Phase 3, 6 Phase 1, 4 Phase 4.
Follow Neoadjuvant Therapy: new trials by email Literature Review of Neoadjuvant Therapy trials Research Report on Neoadjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Neoadjuvant Therapy for Esophageal Cancer Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy | Not applicable | Enrolling by invitation | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 43 | 2028-03-01 | 2025-05-25 |
| Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study Standard of Care - ePRO, Symptom Monitoring | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-02-21 | 2026-09-21 |
| An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC Nivolumab - Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 40 | 2026-11-02 | 2026-10-28 |
| Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 ) Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody - Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Peking University First Hospital | 20 | 2026-11-01 | 2026-10-28 |
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 14 | 2026-10-01 | 2026-08-14 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-28 |
| Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC Firmonertinib combined anlotinib and chemotehrapy - NSCLC (Non-small Cell Lung Cancer), EGFR | Phase 2 | Not yet recruiting | Hubei Cancer Hospital | 29 | 2026-09-21 | 2026-09-08 |
| Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial Bevacizumab combined with iruplinalkib as neoadjuvant therapy in ALK-positive NSCLC: - ALK, NSCLC | Not applicable | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2026-09-15 | 2026-10-13 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks. - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2026-09-03 | 2026-10-27 |
| Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma Becotatug Vedotin (MRG003), Pucotenlimab - Oral Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 32 | 2026-09-01 | 2026-08-17 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response - Lung Neoplasms, Neoadjuvant Therapy | Not applicable | Recruiting | Peking University People's Hospital | 100 | 2026-08-12 | 2026-10-26 |
| QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy - Cervical Cancer, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2026-06-15 | 2026-06-01 |
| Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial Paclitaxel Oral Solution - Non-Small-Cell Lung Cancer, Neoadjuvant Therapy | Not applicable | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 75 | 2026-06-08 | 2026-05-20 |
| Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 49 | 2026-06-03 | 2026-10-02 |
| Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer olaparib combined with trastuzumab and pertuzumab - Elderly Females, HER2 + Breast Cancer | Phase 4 | Recruiting | Wen-Ming Cao | 45 | 2026-05-25 | 2026-07-10 |
| Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib Abemaciclib - Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 150 | 2026-04-30 | 2026-03-05 |
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 182 | 2026-04-20 | 2026-07-09 |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy QL1706 combined with Chemotherapy - Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-04-14 | 2026-09-28 |
| Digital Mind-Body Therapy for Neoadjuvant Breast Cancer DMBT - Neoadjuvant Therapy | Not applicable | Recruiting | Fudan University | 66 | 2026-03-25 | 2026-04-21 |
Showing 20 of 167. Sign in to see all of them.
Breast Neoplasms (30) · Squamous Cell Carcinoma of Head and Neck (12) · Carcinoma, Non-Small-Cell Lung (11) · Stomach Neoplasms (11) · Colorectal Neoplasms (10) · Rectal Neoplasms (9) · Esophageal Squamous Cell Carcinoma (8) · Esophageal Neoplasms (5) · Pancreatic Neoplasms (5) · Colonic Neoplasms (4) · Lung Neoplasms (4) · Adenocarcinoma (3) · Head and Neck Neoplasms (3) · Pathologic Complete Response (3) · Postoperative Complications (3)
Neoplasms (127) · Neoplasms by Site (123) · Digestive System Diseases (53) · Digestive System Neoplasms (52) · Gastrointestinal Diseases (47) · Gastrointestinal Neoplasms (46) · Breast Diseases (31) · Neoplasms by Histologic Type (31) · Skin Diseases (31) · Skin and Connective Tissue Diseases (31) · Neoplasms, Glandular and Epithelial (30) · Carcinoma (29) · Head and Neck Neoplasms (25) · Intestinal Diseases (22) · Intestinal Neoplasms (22)
Neoadjuvant Therapy (15) · Oxaliplatin (11) · tislelizumab (10) · Carboplatin (9) · Surgical Procedures, Operative (9) · Capecitabine (7) · Cisplatin (7) · Drug Therapy (7) · toripalimab (7) · camrelizumab (6) · Albumin-Bound Paclitaxel (5) · S 1 (combination) (5) · pembrolizumab (5) · 130-nm albumin-bound paclitaxel (4) · Esophagectomy (4)
Fudan University (12) · Sun Yat-sen University (9) · Second Affiliated Hospital, Zhejiang University, School of Medicine (6) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (5) · Peking University People's Hospital (4) · Shanghai Pulmonary Hospital, Shanghai, China (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Fujian Medical University Union Hospital (3) · Henan Cancer Hospital (3) · Peking University First Hospital (3) · The First Affiliated Hospital with Nanjing Medical University (3) · West China Hospital (3) · Centre hospitalier de l'Université de Montréal (CHUM) (2) · First Affiliated Hospital of Guangxi Medical University (2)
China (117) · South Korea (4) · Canada (3) · Spain (3) · United States (3) · Germany (2) · Netherlands (2) · Sweden (2) · Taiwan (2) · Turkey (Türkiye) (2) · Belgium (1) · Croatia (1) · Denmark (1) · Egypt (1) · Italy (1)
Weilin Wang (3) · Antoine Desilets, MD, MSc (2) · Jianan Wang (2) · Sen Zhang (2) · Xingchen Peng (2) · Andreas Schneeweiss, MD (1) · Antonio Lacy, PhD (1) · Antonis Valachis, MD, PhD (1) · Audrius Dulskas, PhD (1) · Barbara Smith, MD, PhD (1) · Bin Wang (1) · China Fujian (1) · Chuan Wang (1) · Dietlind L. Wahner-Roedler, M.D. (1)
PMID 29658848, PMID 31679945, PMID 33538338, PMID 16982773, PMID 17848677, PMID 17960012, PMID 18089777, PMID 18784101, PMID 21233014, PMID 21437225, PMID 23683750, PMID 24780112, PMID 24903904, PMID 25049329, PMID 25452445, PMID 28189914, PMID 28490940, PMID 28533474, PMID 29606109, PMID 29658856, PMID 30280658, PMID 30462163, PMID 30715153, PMID 30742122, PMID 31138805, PMID 32665297, PMID 33243986, PMID 33515668, PMID 33796452, PMID 33804419, PMID 34083421, PMID 34241629, PMID 34606846, PMID 34688374, PMID 34844180, PMID 35219300, PMID 35276673, PMID 35427471, PMID 35574368, PMID 35764956, PMID 35767439, PMID 35902798, PMID 36645621, PMID 36922805, PMID 36999830, PMID 37085731, PMID 37409565, PMID 37879536, PMID 38057662, PMID 38553594
2025 (2), 2016 (1), R01CA212138 (1)